PPHI https://validator.w3.org/feed/docs/rss2.html Home Panduan Pemberian Terapi Sistemik untuk Kasinoma Sel Hati: Sebuah Panduan Praktis untuk Klinis Pedoman Nasional Pelayanan Kedokteran (PNPK) Tata Laksana Karsinoma Sel Hati pada Dewasa tahun 2022 Wide Benefit, Less Toxic Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240 A Randomized Double-Blind Phase III Trial Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma Privacy Policy Kasus Pria 47 Tahun Pontianak Indonesian consensus on systemic therapies for hepato cellular carcinoma Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis IMbrave150: Exploratory efficacy and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study Overview PPHI Website Kasus Pria 56 Tahun Jakarta IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC) Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma Sorafenib in Advanced Hepatocellular Carcinoma Enhancing Interprofessional Collaboration for Improving Hepatobiliary Diseases Management REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab New treatment paradigm with systemic therapy in intermediate‑stage hepatocellular carcinoma Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study Virtual Liver Update 2022 – Clinical Associate Prof Tai Wai Meng David, Singapore Session Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges Immune Checkpoint Inhibitors in the Treatment of HCC Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment Combination Cancer Immunotherapy in Hepatocellular Carcinoma Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? Clinically approved combination immunotherapy: Current status, limitations, and future perspective Immunotherapy for advanced hepatocellular carcinoma a focus on special subgroups Combination therapy for advanced hepatocellular carcinoma do we see the light at the end of the tunnel GUIDELINES  Advances in immunotherapy for hepatocellular carcinoma Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects Hepatocellular carcinoma Management of Hepatocellular Carcinoma in Japan JSH Consensus Statements and Recommendations 2021 Update Systemic treatment of hepatocellular carcinoma: An EASL position paper 2022 Update of BCLC Treatment Algorithm of HCC: What’s New for Interventional Radiologists ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19 Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology APASL 2020 Annual Meeting in Bali, Indonesia Drug Induced Liver Injury Symposium Community Posts